Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA positively assesses COVID-19 vaccine from Pfizer and BioNTech 

By Brian Buntz | December 8, 2020

Pfizer BioNTechFDA staff released data today confirming the performance of the BNT162b2 COVID-19 vaccine candidate from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX). 

The vaccine appears to be on track to receive emergency use authorization to inoculate Americans at least 16 years old based on its Phase 3 trial involving roughly 44,000 participants. 

The average efficacy rate for the vaccine in the trial was 95%, and the vaccine demonstrated similar efficacy across age groups, genders, ethnic groups and patients with medical comorbidities. 

The FDA noted in its remarks that the BNT162b2 vaccine “did not raise specific safety concerns,” although common side effects include injection site reactions, fatigue, headache and muscle pain. 

Four clinical trial volunteers developed Bell’s palsy, a form of partial facial paralysis, but the FDA determined that they were likely unrelated to the vaccine. The agency recommended surveillance for cases of Bell’s palsy once the vaccine is available. The agency also highlighted the possibility that a small number of vaccine recipients experienced allergic reactions.

U.K. authorities recently warned people with severe allergies to avoid the vaccine after two people suffered anaphylactoid reactions.

Pfizer and BioNTech filed for emergency use authorization (EUA) for the vaccine on Nov. 20. 

The FDA documents stated there was insufficient data to determine whether to recommend the vaccine to pregnant women, immunocompromised people or people under the age of 16.  

An advisory committee known as the Vaccines and Related Biological Products Advisory Committee (VRBAC) will meet on Dec. 10 to evaluate the vaccine’s prospects for EUA. The panel will meet again on Dec. 17 to discuss granting emergency use authorization to Moderna’s COVID-19 vaccine candidate. 


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, FDA, Pfizer, vaccine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE